LWLawrence Wrabetz

Lawrence Wrabetz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lawrence Wrabetz has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Albee Messing

    Waisman Center and 3 Department of Comparative Biosciences , University of Wisconsin-Madison , Madison, WI 53705 , USA

    5 shared publications
  • Maria Laura Feltri

    Division of Genetics and Cell Biology , San Raffaele Scientific Institute, DIBIT , 20132 Milan , Italy

    4 shared publications
  • Angelo Quattrini

    Division of Neuroscience IRCCS San Raffaele Scientific Institute Milan Italy

    3 shared publications
  • Maurizio D'ANtonio

    Division of Genetics and Cell Biology , San Raffaele Scientific Institute, DIBIT , 20132 Milan , Italy

    3 shared publications
  • Stefano Carlo Previtali

    Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

    3 shared publications
  • Daniele Imperiale

    DIBIT and 2Department of Neurology, San Raffaele Scientific Institute, 20132 Milano, Italy, 3Department of Neurology, University of Würzburg, D97080 Würzburg, Germany, 4Biology Department, Boston College, Chestnut Hill, Massachusetts 02467, and 5Waisman Center and Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin 53706

    2 shared publications

Latest Publications

  • Open Access

    P0S63del impedes the arrival of wild-type P0 glycoprotein to myelin in CMT1B mice

    by Pietro Fratta, Paola Saveri, Desiree Zambroni, Cinzia Ferri, Elisa Tinelli, Albee Messing, Maurizio D'ANtonio, Maria Laura Feltri, Lawrence Wrabetz

    More than 120 mutations in the Myelin Protein Zero gene (MPZ, P0) cause various forms of hereditary neuropathy. Two human mutations encoding either P0S63C or P0S63del have been shown to cause demyelination in mice through different gain of function pathomechanisms. P0S63del, for example, is retained in the endoplasmic reticulum (ER) and elicits a pathogenetic unfolded protein response (UPR). As P0 likely forms oligomers, another gain of abnormal function could include a dominant-negative interaction between P0S63del and normal P0 (P0wt). To test this idea, we generated a transgenic mouse that expressed a form of P0wt with a myc epitope tag at the C terminus (P0ct-myc). We show that P0ct-myc is trafficked and functions like P0wt, thus providing a new tool to study P0 in vivo. In mice that express both P0ct-myc and P0S63del, P0S63del specifically delays the transit of P0ct-myc through the ER and reduces the level of P0wt in the myelin sheath by half—a level previously shown to cause demyelination in mice and humans. Surprisingly, P0ct-myc does not co-immunoprecipitate with P0S63del, suggesting an indirect interaction. Thus, P0S63del causes not only a UPR-related toxic mechanism, but also a dominant-negative effect on P0wt that probably contributes to demyelinating neuropathy.


  • Myelin under stress

    by Maurizio D'ANtonio, M. Laura Feltri, Lawrence Wrabetz

    The capacity to fold proteins properly is fundamental for cell survival. Secreted and transmembrane proteins are synthesized in the endoplasmic reticulum (ER), an organelle that has the ability to discriminate between native and nonnative proteins, in a process called protein quality control. When folding is not properly achieved, misfolded proteins can accumulate. The terminally misfolded proteins are typically retrotranslocated into the cytoplasm for degradation by the proteasome, in a process known as endoplasmic reticulum‐associated degradation. However, if the degradation is insufficient, accumulation of abnormal proteins in the ER activates the unfolded protein response (UPR), a complex set of new signals aimed to reduce further the load of abnormal protein in the ER. Massive synthesis of myelin lipids and proteins is necessary to support myelinogenesis. Not surprisingly, therefore, ER stress (including the UPR), the proteasome, and autophagy (lysosomes) have been implicated in myelin disorders, such as Pelizaeus‐Merzbacher disease and vanishing white matter disease in the central nervous system and Charcot‐Marie‐Tooth neuropathies in the peripheral nervous system. Here we discuss recent evidence supporting an important role for ER stress in myelin disorders.


  • Myelin Structural Integrity in a Model for Human Early-Onset CMT1B

    by Michelle Crowther, Brian Shy, Adrienne M. Luoma, Lawrence Wrabetz, Michael E. Shy, Daniel A. Kirschner

  • Open Access

    Molecular mechanisms of inherited demyelinating neuropathies

    by Steven S. Scherer, Lawrence Wrabetz

    The past 15 years have witnessed the identification of more than 25 genes responsible for inherited neuropathies in humans, many associated with primary alterations of the myelin sheath. A remarkable body of work in patients, as well as animal and cellular models, has defined the clinical and molecular genetics of these illnesses and shed light on how mutations in associated genes produce the heterogeneity of dysmyelinating and demyelinating phenotypes. Here, we review selected recent developments from work on the molecular mechanisms of these disorders and their implications for treatment strategies.


  • Open Access

    Different Intracellular Pathomechanisms Produce DiverseMyelin Protein ZeroNeuropathies in Transgenic Mice

    by Lawrence Wrabetz, Maurizio D’antonio, Maria Pennuto, Gabriele Dati, Elisa Tinelli, Pietro Fratta, Stefano Previtali, Daniele Imperiale, Jurgen Zielasek, Klaus Toyka, et al.

    Missense mutations in 22 genes account for one-quarter of Charcot–Marie–Tooth (CMT) hereditary neuropathies.Myelin Protein Zero(MPZ,P0) mutations produce phenotypes ranging from adult demyelinating (CMT1B) to early onset [Déjérine-Sottas syndrome (DSS) or congenital hypomyelination] to predominantly axonal neuropathy, suggesting gain of function mechanisms. To test this directly, we produced mice in which either theMpzS63C (DSS) orMpzS63del (CMT1B) transgene was inserted randomly, so that the endogenousMpzalleles could compensate for any loss of mutant P0 function. We show that either mutant allele produces demyelinating neuropathy that mimics the corresponding human disease. However, P0S63C creates a packing defect in the myelin sheath, whereas P0S63del does not arrive to the myelin sheath and is instead retained in the endoplasmic reticulum, where it elicits an unfolded protein response (UPR). This is the first evidence for UPR in association with neuropathy and provides a model to determine whether and how mutant proteins can provoke demyelination from outside of myelin.


  • Characterization of a Schwann cell enhancer in the myelin basic protein gene

    by Carla Taveggia, Antonella Pizzagalli, Ernesta Fagiani, Albee Messing, M. Laura Feltri, Lawrence Wrabetz

    Oligodendrocytes and Schwann cells use diverse regulatory elements to transcribe myelin basic protein (Mbp). For example, an enhancer 9.0 kb upstream of Mbp (MbpSCE1) activated either the proximal Mbp or hsp68 promoters only in Schwann cells in transgenic mice. Here, we analyze MbpSCE1 in vitro and in vivo and show that MbpSCE1 also activates another myelin gene, Mpz, specifically in Schwann cells in transgenic mice. Surprisingly, although MbpSCE1 behaves as an enhancer in Schwann cells, we show here for the first time that it also activates transcription robustly in cultured oligodendrocytes, but only from its original genomic position. Diverse nuclear proteins binding at distinct combinations of DNA elements in the two cell types may account for cell-specific MbpSCE1 function. A further surprise is that MbpSCE1 activation does not depend on consensus binding sites for the myelin-associated PPARbeta or Krox 20 transcription factors. Finally, chromatin context augments activation of MbpSCE1. Therefore, MbpSCE1 is active in both Schwann cells and oligodendrocytes, but by diverse mechanisms.


  • Open Access

    P0 Glycoprotein Overexpression Causes Congenital Hypomyelination of Peripheral Nerves

    by Lawrence Wrabetz, Maria Laura Feltri, Angelo Quattrini, Daniele Imperiale, Stefano Previtali, Maurizio D'ANtonio, Rudolf Martini, Xinghua Yin, Bruce D. Trapp, Lei Zhou, et al.

    We show that normal peripheral nerve myelination depends on strict dosage of the most abundantly expressed myelin gene, myelin protein zero (Mpz). Transgenic mice containing extra copies of Mpz manifested a dose-dependent, dysmyelinating neuropathy, ranging from transient perinatal hypomyelination to arrested myelination and impaired sorting of axons by Schwann cells. Myelination was restored by breeding the transgene into the Mpz-null background, demonstrating that dysmyelination does not result from a structural alteration or Schwann cell-extrinsic effect of the transgenic P0 glycoprotein. Mpz mRNA overexpression ranged from 30–700%, whereas an increased level of P0 protein was detected only in nerves of low copy-number animals. Breeding experiments placed the threshold for dysmyelination between 30 and 80% Mpz overexpression. These data reveal new points in nerve development at which Schwann cells are susceptible to increased gene dosage, and suggest a novel basis for hereditary neuropathy.


  • Peripheral Nerve Dysmyelination Due to P0 Glycoprotein Overexpression Is Dose‐Dependent

    by Angelo Quattrini, Maria Laura Feltri, Stefano Previtali, Marina Fasolini, Albee Messing, Lawrence Wrabetz

    We have previously shown that increased dosage of the mouse protein zero gene (Mpz) causes a dysmyelinating neuropathy in transgenic (Tg80) mice. To ask whether the dysmyelination is dose dependent, we inbred one of the Tg80 lines and compared the resulting phenotype in homozygous and heterozygous mice. Whereas heterozygous mice (30% overexpression) have only transient peripheral nerve hypomyelination at two weeks after birth and normal myelin at four weeks after birth, homozygous mice demonstrated more severely hypomyelinated nerves. In the latter, many Schwann cells had achieved a one‐to‐one relationship with large axons but formed no myelin at four weeks after birth. Expression analysis confirmed a doubling of Mpz overexpression in the sciatic nerves of the homozygous mice. Thus, a threshold exists for Mpz overexpression, above which dysmyelination results. These data have important implications for replacement therapy in Charcot‐Marie‐Tooth 1B neuropathies due to loss of P0 function.